Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B

Table 2

Clinical demographics and clinical characteristics of patients in noncirrhosis and cirrhosis groups.

	Total (N = 694)	Noncirrhosis (N = 661)^#	Cirrhosis (N = 33)^##	value
Age, yr	42 (34, 52)	42 (33, 52)	40 (35, 49)	0.605
Male, N (%)	360 (52)	335 (51)	25 (76)	0.000
ALT, U/L	21 (11, 53)	16 (10, 51)	107 (53, 448)	0.000
AST, U/L	26 (19, 46)	23 (19, 40)	99 (47, 376)	0.000
BUN, mmol/L	4.7 ± 1.5	4.7 ± 1.5	4.7 ± 1.3	0.858
Cr, μmol/L	67 (57, 79)	79 (67, 88)	67 (60, 80)	0.374
RBC, 10^12/L	4.7 ± 0.5	4.7 ± 0.5	4.5 ± 0.5	0.021
PLT, 10^9/L	199 ± 61	203 ± 60	141 ± 42	0.000
WBC, 10^9/L	5.9 ± 3.0	5.9 ± 3.1	4.9 ± 1.5	0.001
Glucose, mmol/L	4.8 (4.4, 5.2)	4.7 (4.4, 5.2)	4.9 (4.4, 5.5)	0.462
sGDNF, pg/ml	25.2 (11.4, 29.5)	23.5 (10.9, 29.5)	33.8 (29.3, 39.4)	0.000

Noncirrhosis is defined by health controls and F0–F3; cirrhosis is defined by F4. The data are expressed as mean ± standard deviation or median (25%–75%). ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; PLT, platelet count; RBC, red blood cell; sGDNF, serum GDNF; WBC, white blood cell.